[COVID-19 vaccination in dialysis and kidney transplant patients]. / Vaccination anti-COVID-19 chez les patients dialysés et transplantés rénaux.
Nephrol Ther
; 17(4): 208-213, 2021 Aug.
Article
em Fr
| MEDLINE
| ID: mdl-34305020
ABSTRACT
Patients with end stage renal disease, including dialysis and kidney transplantation, have a high risk of severe COVID-19. In these populations, post-COVID-19 humoral response is prolonged until 6 months post-infection. However, post-vaccination humoral responses are frequently weak even when positive, notably in kidney transplant patients treated with belatacept. Actually, after 2 injectionos of mRNA vaccines, humoral response rates are 80-95% in dialysis patients, 30-50% in transplant patients, and about 5% in transplant patients treated with belatacept. These results have led to propose a 3rd injection of mRNA vaccine in dialysis and transplant patients in France. Numerous questions, regarding cellular responses, durability of response and clinical efficacy of vaccines remain in these high risk populations.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diálise Renal
/
Transplante de Rim
/
Transplantados
/
Vacinas contra COVID-19
Limite:
Humans
Idioma:
Fr
Revista:
Nephrol Ther
Assunto da revista:
NEFROLOGIA
/
TERAPEUTICA
Ano de publicação:
2021
Tipo de documento:
Article